NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中東及非洲的痛經治療市場-至2028年的產業趨勢與預測

Middle East and Africa Menstrual Cramps Treatment Market - Industry Trends and Forecast to 2028

出版商 Data Bridge Market Research Private Limited 商品編碼 977680
出版日期 內容資訊 英文 100 Pages
商品交期: 3-5個工作天內
價格
中東及非洲的痛經治療市場-至2028年的產業趨勢與預測 Middle East and Africa Menstrual Cramps Treatment Market - Industry Trends and Forecast to 2028
出版日期: 2020年11月01日內容資訊: 英文 100 Pages
簡介

中東及非洲的痛經治療的市場規模,預計從2021年到2028年的預測期間以6.2%的年複合成長率擴大。這個新的市場報告,包含2018年的成果,從2019年作為基準年,2020年至2027年的預測資料。

本報告提供中東及非洲的痛經治療市場相關調查,市場概要,以及各類型,各治療類型,各處方模式,各給藥途徑,各終端用戶,各流通管道,各國的趨勢,及加入此市場的主要企業簡介等資訊

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 開發平台分析

  • 中東、非洲的痛經治療市場,開發平台分析

第5章 中東及非洲的痛經治療市場:法規

第6章 重要考察

  • 中東、非洲的痛經治療市場:採用率
    • 採用的促進要素與阻礙
  • 行銷費用

第6章 付款者

第6章 藥局的冷/熱片的市場佔有率

第7章 流行病學

第8章 COVID-19對中東及非洲的痛經治療市場的影響

  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 由於COVID-19期間中的市場參與者的策略性舉措
  • 結論

第9章 市場概要

  • 促進因素
    • 經痛的盛行率上升
    • 技術的進步
    • 為了開發創新藥物和治療方法的研究開發增加
    • 對女性的醫療保健的政府舉措
    • 治療選擇數的增加
  • 阻礙因素
    • 產品回收
    • 女性的生殖健康相關意識的缺乏
    • 子宮內膜切除和子宮切除術的成本高
  • 市場機會
    • 經痛相關的意識高漲
    • 由於主要的市場參與者的策略性舉措
    • 可支配所得的增加
  • 課題
    • 傳統的家族價值導致未治療
    • 長期治療相關的副作用和併發症
    • 補充替代療法的有效性

第10章 中東及非洲的痛經治療市場,各類型

  • 概要
  • 原發性經痛
  • 次發性經痛

第11章 中東及非洲的痛經治療市場,各治療類型

  • 概要
  • 投藥
    • 第一次治療
    • 第二次治療
  • 治療
    • 溫熱療法
    • 行動諮詢
    • 飲食和維他命
  • 手術
    • 子宮內膜切除
    • 子宮切除術
  • 其他

第12章 中東及非洲的痛經治療市場,各處方模式

  • 概要
  • 成藥
  • 處方藥

第13章 中東及非洲的痛經治療市場,各給藥途徑

  • 概要
  • 口服
    • 平板電腦
    • 藥丸
    • 膠囊
    • 其他
  • 非口服
    • 點滴
    • 皮下
    • 其他
  • 植入
  • 其他

第14章 中東及非洲的痛經治療市場,各終端用戶

  • 概要
  • 醫院
  • 專門中心
  • 門診外科中心
  • 其他

第15章 中東及非洲的痛經治療市場,各流通管道

  • 概要
  • 藥局
    • 院內
    • 零售
  • 直接競標
  • 零售
  • 其他

第16章 中東及非洲的痛經治療市場,各地區

  • 中東、非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 以色列
    • 科威特
    • 埃及
    • 其他

第17章 中東及非洲的痛經治療市場:企業形勢

  • 企業佔有率分析:中東、非洲

第18章 SWOT分析

第19章 企業簡介

  • GLAXOSMITHKLINE PLC.
  • JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
  • TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
  • ABBVIE INC.
  • MYLAN N. V. (A PART OF VIATRIS INC.).
  • ALVOGEN
  • BAYER AG
  • BEURER GMBH
  • BIOELECTRONICS CORPORATION
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • COLOR SEVEN CO., LTD.
  • CUMBERLAND PHARMACEUTICALS INC.
  • LIVIA
  • LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
  • MYOVANT SCIENCES LTD.
  • NOBELPHARMA CO., LTD.
  • OBSEVA
  • PFIZER INC.
  • PMS4PMS, LLC
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.

第20章 問卷調查

第21章 相關報告

目錄

Middle East and Africa menstrual cramps treatment market is projected to register a CAGR of 6.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Middle East and Africa Menstrual Cramps Treatment Market, By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment Type (Medication, Therapy, Surgery, Others), Mode of Prescription (Over the Counter, Prescription), Route of Administration (Oral, Parenteral, Implants, Others), End User (Hospitals, Specialty Centers, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Pharmacies, Retail Sales, Direct Tender, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of Middle East and Africa menstrual cramps treatment market are:

  • Rising technological advancement
  • Rise in awareness about dysmenorrhea

Market Players:

The key market players for Middle East and Africa menstrual cramps treatment market are listed below:

  • Bayer AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Mylan N. V. (a part of Viatris Inc.)
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • AbbVie Inc.
  • LIVIA
  • Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 DBMR MARKET POSITION GRID
  • 2.9 VENDOR SHARE ANALYSIS
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

  • 4.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

  • 6.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE
    • 6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS
  • 6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
  • 8.5 CONCLUSION

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 GROWING PREVALENCE OF DYSMENORRHEA
    • 9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS
    • 9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES
    • 9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE
    • 9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS
  • 9.2 RESTRAINTS
    • 9.2.1 PRODUCT RECALLS
    • 9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN
    • 9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY
  • 9.3 OPPORTUNITIES
    • 9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA
    • 9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
    • 9.3.3 RISING DISPOSABLE INCOME
  • 9.4 CHALLENGES
    • 9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT
    • 9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT
    • 9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

  • 10.1 OVERVIEW
  • 10.2 PRIMARY DYSMENORRHEA
  • 10.3 SECONDARY DYSMENORRHEA

11 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

  • 11.1 OVERVIEW
  • 11.2 MEDICATION
    • 11.2.1 FIRST LINE TREATMENT
      • 11.2.1.1 Nonhormonal Therapy
        • 11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs
        • 11.2.1.1.1.1 Ibuprofen
        • 11.2.1.1.1.2 Naproxen
        • 11.2.1.1.1.3 Celecoxib
        • 11.2.1.1.1.4 Mefenamic Acid
        • 11.2.1.1.1.5 Meclofenamate
        • 11.2.1.1.2 Acetaminophen
      • 11.2.1.2 Hormonal Replacement Therapy y
        • 11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)
        • 11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol
        • 11.2.1.2.1.2 Extended-Cycle Oral Contraceptives
        • 11.2.1.2.2 Extended-Cycle Oral Contraceptives
        • 11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol
        • 11.2.1.2.2.2 Others
        • 11.2.1.2.3 Other
        • 11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol
        • 11.2.1.2.3.2 Etonogestrel Implant
        • 11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System
        • 11.2.1.2.3.4 Medroxyprogesterone Shot
      • 11.2.1.3 Diuretic
        • 11.2.1.3.1 Spironolactone
        • 11.2.1.3.2 Ammonium Chloride
      • 11.2.1.4 Antidepressants
    • 11.2.2 SECOND LINE TREATMENT
      • 11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy
      • 11.2.2.2 Ammonium Chloride
  • 11.3 THERAPY
    • 11.3.1 HEAT THERAPY
      • 11.3.1.1 Patch
      • 11.3.1.2 Wrap
      • 11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)
    • 11.3.2 BEHAVIORAL COUNSELING
      • 11.3.2.1 Desensitization-Based Procedures
      • 11.3.2.2 Coping Strategies
      • 11.3.2.3 Imagery
      • 11.3.2.4 Hypnotherapy
      • 11.3.2.5 Others
    • 11.3.3 DIET AND VITAMINS
      • 11.3.3.1 Vitamin E
      • 11.3.3.2 Vitamin B
      • 11.3.3.3 Vitamin D
      • 11.3.3.4 Others
  • 11.4 SURGERY
    • 11.4.1 ENDOMETRIAL ABLATION
    • 11.4.2 HYSTERECTOMY
  • 11.5 OTHERS

12 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

  • 12.1 OVERVIEW
  • 12.2 OVER THE COUNTER
  • 12.3 PRESCRIPTION

13 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 ORAL
    • 13.2.1 TABLETS
    • 13.2.2 PILLS
    • 13.2.3 CAPSULE
    • 13.2.4 OTHERS
  • 13.3 PARENTERAL
    • 13.3.1 INTRAVENOUS
    • 13.3.2 SUBCUTANEOUS
    • 13.3.3 OTHERS
  • 13.4 IMPLANTS
  • 13.5 OTHERS

14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CENTERS
  • 14.4 AMBULATORY SURGICAL CENTERS
  • 14.5 OTHERS

15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 PHARMACIES
    • 15.2.1 HOSPITAL
    • 15.2.2 RETAIL
  • 15.3 DIRECT TENDER
  • 15.4 RETAIL SALES
  • 15.5 OTHERS

16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

  • 16.1 MIDDLE EAST & AFRICA
    • 16.1.1 SAUDI ARABIA
    • 16.1.2 SOUTH AFRICA
    • 16.1.3 UAE
    • 16.1.4 ISRAEL
    • 16.1.5 KUWAIT
    • 16.1.6 EGYPT
    • 16.1.7 REST OF MIDDLE EAST & AFRICA

17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

  • 19.1 GLAXOSMITHKLINE PLC.
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENT
  • 19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANLYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS
  • 19.4 ABBVIE INC.
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 MYLAN N. V. (A PART OF VIATRIS INC.).
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENT
  • 19.6 ALVOGEN
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 PRODUCT PORTFOLIO
    • 19.6.3 RECENT DEVELOPMENT
  • 19.7 BAYER AG
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 REVENUE ANALYSIS
    • 19.7.3 PRODUCT PORTFOLIO
    • 19.7.4 RECENT DEVELOPMENTS
  • 19.8 BEURER GMBH
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 PRODUCT PORTFOLIO
    • 19.8.3 RECENT DEVELOPMENT
  • 19.9 BIOELECTRONICS CORPORATION
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENT
  • 19.11 COLOR SEVEN CO., LTD.
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENTS
  • 19.12 CUMBERLAND PHARMACEUTICALS INC.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 LIVIA
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 PRODUCT PORTFOLIO
    • 19.13.3 RECENT DEVELOPMENTS
  • 19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 REVENUE ANALYSIS
    • 19.14.3 PRODUCT PORTFOLIO
    • 19.14.4 RECENT DEVELOPMENTS
  • 19.15 MYOVANT SCIENCES LTD.
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 NOBELPHARMA CO., LTD.
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 OBSEVA
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 PRODUCT PORTFOLIO
    • 19.17.3 RECENT DEVELOPMENTS
  • 19.18 PFIZER INC.
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENTS
  • 19.19 PMS4PMS, LLC
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENT
  • 19.20 SANOFI
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENT
  • 19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS
  • TABLE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 3 MIDDLE EAST & AFRICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REG

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
  • FIGURE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION
  • FIGURE 3 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
  • FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028
  • FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET
  • FIGURE 14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020
  • FIGURE 15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
  • FIGURE 16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 18 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020
  • FIGURE 19 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)
  • FIGURE 20 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)
  • FIGURE 21 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
  • FIGURE 22 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020
  • FIGURE 23 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)
  • FIGURE 24 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)
  • FIGURE 25 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE
  • FIGURE 26 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
  • FIGURE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
  • FIGURE 28 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
  • FIGURE 29 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020
  • FIGURE 31 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
  • FIGURE 32 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 33 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 34 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • FIGURE 35 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
  • FIGURE 36 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 37 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 38 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)
  • FIGURE 39 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)
  • FIGURE 40 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 41 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 42 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)
  • FIGURE 43 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)